Omeros Corp., of Seattle, reported additional data from the ongoing phase II trial testing OMS721 in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) at the combined annual meetings of the Center for International Blood & Marrow Transplant Research and the American Society for Blood and Marrow Transplantation in Orlando, Fla. Consistent with previously reported results, statistically significant and clinically meaningful improvements in TMA disease activity were observed over the course of treatment, specifically in mean platelet count, mean LDH and mean haptoglobin. Mean creatinine also improved but did not reach statistical significance. Omeros plans to meet with regulators to design a phase III program for OMS721, a MASP-2-targeting drug.